Skip to main content

Market Overview

Pfizer Starts Early-Stage Study Of Oral Antiviral COVID-19 Drug

Share:

Pfizer Inc (NYSE: PFEhas started an early-stage U.S. trial of an oral COVID-19 antiviral therapy, dubbed as PF-07321332.

  • The drugmaker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany's BioNTech SE (NASDAQ: BNTX), said the antiviral candidate showed potent activity against SARS-CoV-2 in lab studies.
  • The Phase 1 study progressed to multiple ascending doses after completing the dosing of single ascending doses in healthy adults.
  • PF-07321332 is a protease inhibitor that prevents the virus from replicating in cells.
  • The company is also studying an intravenously administered antiviral candidate in an early-stage trial in hospitalized COVID-19 patients.
  • Pfizer's candidate is behind two other oral antiviral therapies, which are in mid-stage trials:
    •  Molnupiravir - in development by Merck & Co (NYSE: MRK) with Ridgeback Bio. Recent interim data showed that the antiviral significantly reduced the infectious virus in COVID-19 patients after five treatment days.
    • Roche Holdings AG (OTCMKTS: RHHBY) and Atea Pharmaceuticals Inc (NASDAQ: AVIR) are developing AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The first patient was dosed in February
  • Gilead Sciences' remdesivir is currently the only FDA-approved drug for the treatment of COVID-19.
  • The FDA granted an emergency authorization to intravenous therapies from Eli Lilly bamlanivimab alone and in combination with etesevimab, and a combination therapy from Regeneron.
  • Price Action: PFE shares are trading 0.97% lower at $35.65 in market hours on the last check Tuesday.
 

Related Articles (PFE + BNTX)

View Comments and Join the Discussion!

Posted-In: COVID-19 Coronavirus Phase 1 TrialBiotech News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com